A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)

NCT00686595 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

BIOLOGICAL: Infliximab

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]